| |
SC-560
Inhibition, SEM (%)
|
Celecoxib
Inhibition, SEM (%)
|
p-value
|
|---|
|
CRN-pts (N/n = 15/26)
|
68.8 ± 4.5
|
53.7 ± 5.1
|
0.035*
|
|
Ctrls (N/n = 10/19)
|
80.6 ± 4.8
|
52.6 ± 10.3
|
0.028*
|
|
p-value
|
0.10
|
0.91
| |
- Horizontal p-values to the right show inhibition by SC-560 compared to inhibition by Celecoxib for CRN-pts and ctrls. Vertical p-values at the bottom show CRN-pts compared to ctrls for SC-560 inhibition and Celecoxib inhibition. Inhibition calculated as percentage selective COX-inhibition of total COX-inhibition. Total COX-inhibition defined as selective COX-inhibition + indomethacin inhibition. Percentage drop reflects the overall decreased activity. CRN-pts represent values for biopsies from colorectal neoplasia patients and ctrls values are for biopsies from patients without colorectal neoplasia. N = number of patients, n = number of biopsies, in parenthesis (N/n). * p-value < 0.05
